Niagen Bioscience secures exclusive rights for Parkinson’s treatment

LOS ANGELES - Niagen Bioscience, Inc. (NASDAQ:NAGE), whose stock has surged nearly 400% over the past year according to InvestingPro data, has entered into a worldwide exclusive commercial license agreement with Norway’s Haukeland University Hospital for rights to develop its nicotinamide riboside (Niagen) molecule as a potential treatment for Parkinson’s Disease.

The agreement grants Niagen Bioscience exclusive rights to intellectual property, know-how, and data that could support future regulatory filings in the EU and elsewhere. With this license, the company, which currently generates annual revenue of $107.92M with a healthy gross margin of 62.5%, becomes the only entity permitted to seek regulatory approval for a pharmaceutical nicotinamide riboside therapy for Parkinson’s patients.

Central to the agreement is access to data from the NOPARK trial, a recently completed phase III clinical study involving 400 individuals with early-stage Parkinson’s Disease across 12 Norwegian sites. The double-blind, placebo-controlled trial evaluated 500 mg of nicotinamide riboside twice daily versus placebo over 52 weeks, with results expected to be published by the end of 2025.

"This is an important milestone in our efforts to bring a potentially disease-modifying treatment for PD closer to patients," said Professor Charalampos Tzoulis, who leads the NOPARK study at Haukeland University Hospital.

The collaboration builds on a partnership dating back to 2018 and encompasses several clinical trials assessing Niagen’s therapeutic potential for Parkinson’s, including the phase I/IIa NADPARK study previously published in Cell Metabolism.

In connection with the license agreement, Niagen Bioscience has established a wholly owned subsidiary to advance its regulated drug development efforts.

The information in this article is based on a company press release statement. According to InvestingPro analysis, Niagen maintains strong financial health with a current ratio of 3.66 and operates with moderate debt levels. While the stock trades at a premium valuation with a P/E ratio of 75.1, InvestingPro subscribers have access to 15+ additional key insights and comprehensive financial metrics to make informed investment decisions.

In other recent news, Niagen Bioscience Inc. has reported a robust first quarter of 2025, with total net sales reaching $30.5 million, a 38% increase from the previous year. The company’s net income also saw a significant turnaround, rising to $5.1 million from a net loss of $500,000 in Q1 2024. In addition to these financial achievements, Niagen Bioscience has been granted Orphan Drug Designation and Rare Pediatric Disease Designation by the FDA for its Niagen product in treating Ataxia Telangiectasia. This underscores the potential value of Niagen in addressing rare disease populations.

The company has also announced promising results from a clinical study on Werner Syndrome, which demonstrated the effectiveness of Niagen in significantly raising blood NAD+ levels and improving cardiovascular and skin health markers. This study, published in Aging Cell, is the first of its kind to show such results in Werner Syndrome patients. Niagen Bioscience’s focus on rare, age-related diseases is further emphasized by these findings, which highlight the therapeutic potential of NAD+ augmentation.

Additionally, Niagen Bioscience has raised its full-year top-line growth outlook to 20-25%, driven by strong e-commerce sales and growth in its Niagen ingredient business. The company’s strategic initiatives, including a focus on marketing efficiency and a U.S.-based supply chain, have contributed to its improved financial performance. Analyst firms have taken note of these developments, with some expressing optimism about the company’s future growth potential.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.